Skip to content
Screener

Aurinia Pharmaceuticals AUPH Cumulative Cost Basis

Cumulative Cost Basis at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$15.63M+173%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$493.74M—
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+35.7%
Enterprise value$1.98B+25.5%
P/E6.6×-18.6×
P/S6.7×+0.8×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemJune 30, 2026December 31, 2025
Leasehold improvements$3,243$3,243
Furniture1,1551,155
Office equipment631631
Computer equipment235235
Total gross property and equipment5,2645,264
Less accumulated depreciation(3,402)(3,153)
Property and equipment, net$1,862$2,111

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's cumulative cost basis?
Aurinia Pharmaceuticals (AUPH) reported cumulative cost basis of $5.26M in Q2 2026.
How has Aurinia Pharmaceuticals's cumulative cost basis changed year-over-year?
Aurinia Pharmaceuticals's cumulative cost basis decreased by 0.0% year-over-year, from $5.26M to $5.26M.
What is the long-term trend for Aurinia Pharmaceuticals's cumulative cost basis?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's cumulative cost basis has grown at a 1.2% compound annual growth rate (CAGR), from $4.97M to $5.26M.
What does cumulative cost basis mean?
The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.

Ask your AI about Aurinia Pharmaceuticals's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude